Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cryoport, Inc.CYRX · Entity 5125 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cryoport, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 91,108 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 10,350 · Balance 91,108 F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | Direct | 67,894 |
Reported balance
After 2026-06-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-08 · Sale · Disposed 23,214 · Balance 67,894 F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.48, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.70 · Expires 2033-06-05 | Direct | 16,077 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Grant · Acquired 16,077 · Balance 16,077 F3: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.48, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2016 Filed Oct 4, 2016 22:13 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 3,424 | $1.97 | $6,745.28 |
DisclosureSEC source: 0001144204-16-126854 · v450015_4.xml · nonDerivative · entry 1 Mandalam Ramkumar · CIK 0001611439 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,492 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.